Abstract:Chikungunya fever is a reemerging and arthropod-borne viral infection caused by Chikungunya virus (CHIKV), which is mainly transmitted by Aedes ssp. mosquitoes. It is found in more than 100 countries worldwide and is a serious public health concern. Typical clinical symptoms of CHIKV infection in humans are acute fever, skin rash, severe joint and muscle pain, chronic arthritis, and prolonged tenosynovitis. The virus may invade the brain and cause death. Mouse models are commonly used, and are powerful experimental animal models for studying CHIKV infection pathogenesis and host-microbe interaction factors, and exploring and evaluating the efficacy and safety of therapeutics and vaccines against CHIKV. This review provides an overview of major recent advances in the understanding of chikungunya from studies in the mouse model.
蒋小武, 朱乐欣, 艾莎珍. 基孔肯雅病毒小鼠感染模型研究进展[J]. 中国人兽共患病学报, 2021, 37(9): 826-832.
JIANG Xiao-wu, ZHU Le-xin, AI Sha-zhen. Research progress in the mouse infection model for Chikungunya virus. Chinese Journal of Zoonoses, 2021, 37(9): 826-832.
[1] Moizeis RNC, Fernandes T, Guedes P, et al.Chikungunya fever: a threat to global public health[J]. Pathog Glob Health, 2018, 112(4): 182-194. DOI:10.1080/20477724.2018.1478777 [2] Cunha MS, Costa PAG, Correa IA, et al.Chikungunya virus: an emergent arbovirus to the South American Continent and a continuous threat to the world[J]. Front Microbiol, 2020, 11(1297): 1-20. DOI:10.3389/fmicb.2020.01297 [3] Morrison CR, Plante KS, Heise MT.Chikungunya virus: current perspectives on a reemerging virus[J]. Microbiol Spectr, 2016, 4(3): 1-14. DOI:10.1128/microbiolspec.EI10-0017-2016 [4] Wahid B, Ali A, Rafique S, et al.Global expansion of chikungunya virus: mapping the 64-year history[J]. Int J Infect Dis, 2017, 58:69-76. DOI:10.1016/j.ijid.2017.03.006 [5] Vairo F, Haider N, Kock R, et al.Chikungunya epidemiology, pathogenesis, clinical features, management, and prevention[J]. Infect Dis Clin North Am, 2019, 33(4): 1003-1025. DOI:10.1016/j.idc.2019.08.006 [6] Bautista-Reyes E, Nunez-Avellaneda D, Alonso-Palomares LA, et al.Chikungunya: molecular aspects, clinical outcomes and pathogenesis[J]. Rev Invest Clin, 2017, 69(6): 299-307. DOI:10.24875/RIC.17002029 [7] Vijayan V, Sukumaran S.Chikungunya virus disease: an emerging challenge for the rheumatologist[J]. J Clin Rheumatol, 2016, 22(4): 203-211. DOI:10.1097/RHU.0000000000000396 [8] Mccarthy MK, Davenport BJJ, Morrison TE.Chronic chikungunya virus disease[M]. Berlin: Springer Berlin Heidelberg,2019:1-26. [9] 徐佩佩,丁细霞. 基孔肯雅病毒实验诊断进展[J]. 中国人兽共患病学报, 2020, 36(1): 60-64. DOI:10.3969/j.issn.1002-2694.2019.00.188 [10] Ganesan VK, Duan B, Reid SP.Chikungunya virus: pathophysiology, mechanism, and modeling[J]. Viruses, 2017, 9(368): 1-14. DOI:10.3390/v9120368 [11] Lu X, Li X, Mo Z, et al.Chikungunya emergency in China: microevolution and genetic analysis for a local outbreak[J]. Virus Genes, 2014, 48(1): 15-22. DOI:10.1007/s11262-013-0991-2 [12] 曹国平, 钟建跃, 郑灿杰, 等. 浙江省衢州市基孔肯雅热疫情流行病学研究[J]. 中国预防医学杂志, 2019, 20(1): 17-20. DOI:10.16506/j.1009-6639.2019.01.006 [13] Pan JH, Fang CF, Yan JY, et al.Chikungunya fever outbreak, Zhejiang Province, China, 2017[J]. Emerg Infect Dis, 2018, 25(6): 1589-1591. DOI:10.3201/eid2508.181212 [14] 田德桥, 陈薇. 基孔肯雅病毒与基孔肯雅热[J]. 微生物与感染, 2016, 11(4): 194-206. [15] Haese NN, Broeckel RM, Hawman DW, et al.Animal models of Chikungunya virus infection and disease[J]. J Infect Dis, 2016, 214(suppl 5): S482-S487. DOI:10.1093/infdis/jiw284 [16] Gomes MC, Mostowy S.The case for modeling human infection in zebrafish[J]. Trends Microbiol, 2020, 28(1): 10-18. DOI:10.1016/j.tim.2019.08.005 [17] Bosco-Lauth AM, Han S, Hartwig A, et al.Development of a hamster model for Chikungunya virus infection and pathogenesis[J]. PLoS One, 2015, 10(6): e0130150. DOI:10.1371/journal.pone.0130150 [18] Barr K, Vaidhyanathan V.Chikungunya in infants and children: Is pathogenesis increasing[J]. Viruses, 2019, 11(294): 1-20. DOI:10.3390/v11030294 [19] G Rardin P, Couderc T, Bintner M, et al. Chikungunya virus-associated encephalitis: a cohort study on La Réunion Island, 2005-2009[J]. Neurology, 2016, 86(1): 94-102. DOI:10.1212/WNL.0000000000002234 [20] Couderc T, Chr Tien F, Schilte C, et al.A mouse model for Chikungunya: young age and inefficient type-I interferon signaling are risk factors for severe disease[J]. PLoS Pathog, 2008, 4(2): 1-12. DOI:10.1371/journal.ppat.0040029 [21] Sarah A Ziegler, Liang Lu, Amelia PA.Travassos da Rosa, et al. An animal model for studying the pathogenesis of chikungunya virus infection[J]. Am J Trop Med Hyg, 2008, 79(1): 133-139. DOI:10.4269/ajtmh.2008.79.133 [22] Das THJ, Bandjee Mcj, Maquart M, et al.Multifaceted innate immune responses engaged by astrocytes, microglia and resident dendritic cells against chikungunya neuroinfection[J]. J Gen Virol, 2015, 96(Pt2): 294-310. DOI:10.1099/vir.0.071175-0 [23] Zhang HL, Dong HL, Zhang YN, et al.Visualization of chikungunya virus infection in vitro and in vivo[J]. Emerg Microbes Infect, 2019, 8(1): 1574-1583. DOI:10.1080/22221751.2019.1682948 [24] Saraswat S, Athmaram TN, Parida M, et al.Expression and characterization of yeast derived Chikungunya virus like particles (CHIK-VLPs) and its evaluation as a potential vaccine candidate[J]. PLoS Negl Trop Dis, 2016, 10(7): e0004782. DOI:10.1371/journal.pntd.0004782 [25] Lam S, Nyo M, Phuektes P, et al.A potent neutralizing IgM mAb targeting the N218 epitope on E2 protein protects against Chikungunya virus pathogenesis[J]. mAbs, 2015, 7(6): 1178-1194. DOI:10.1080/19420862.2015.1083664 [26] Lam S, Chen H, Chen CK, et al.Antiviral phosphorodiamidate morpholino oligomers are protective against Chikungunya virus infection on cell-based and murine models[J]. Sci Rep, 2015, 5(12727): 1-14. DOI:10.1038/srep12727 [27] Burt FJ, Chen W, Miner JJ, et al.Chikungunya virus: an update on the biology and pathogenesis of this emerging pathogen[J]. Lancet Infect Dis, 2017, 17(4): e107-e117. DOI:10.1016/S1473-3099(16)30385-1 [28] Roques P, Goupil BA, Mcnulty MA, et al.Novel lesions of bones and joints associated with Chikungunya virus infection in two mouse models of disease: new insights into disease pathogenesis[J]. PLoS One, 2016, 11(5): e0155243. DOI:10.1371/journal.pone.0155243 [29] Teo TH, Lum FM, Claser C, et al.A pathogenic role for CD4+ T cells during Chikungunya virus infection in mice[J]. J Immunol, 2013, 190(1): 259-269. DOI:10.4049/jimmunol.1202177 [30] Morrison TE, Oko L, Montgomery SA, et al.A mouse model of Chikungunya virus-induced musculoskeletal inflammatory disease[J]. Am J Pathol, 2011, 178(1): 32-40. DOI:10.1016/j.ajpath.2010.11.018 [31] Morrison TE.Animal models for Chikungunya virus and Zika virus [M]. Saltlake USA: Academic Press,2018:317-346. [32] Dagley A, Ennis J, Turner JD, et al.Protection against Chikungunya virus induced arthralgia following prophylactic treatment with adenovirus vectored interferon (mDEF201)[J]. Antiviral Res, 2014, 108:1-9. DOI:10.1016/j.antiviral.2014.05.004 [33] Gardner CL, Hritz J, Sun C, et al.Deliberate attenuation of Chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design[J]. PLoS Negl Trop Dis, 2014, 8(2): e2719. DOI:10.1371/journal.pntd.0002719 [34] Nakaya HI, Gardner J, Poo YS, et al.Gene profiling of Chikungunya virus arthritis in a mouse model reveals significant overlap with rheumatoid arthritis[J]. Arthritis Rheum, 2012, 64(11): 3553-3563. DOI:10.1002/art.34631 [35] Gardner J, Anraku I, Le TT, et al.Chikungunya virus arthritis in adult wild-type mice[J]. J Virol, 2010, 84(16): 8021-8032. DOI:10.1128/JVI.02603-09 [36] Chen W, Foo SS, Taylor A, et al.Bindarit, an inhibitor of monocyte chemotactic protein synthesis, protects against bone loss induced by chikungunya virus infection[J]. J Virol, 2015, 89(1): 581-593. DOI:10.1128/JVI.02034-14 [37] Werneke SW, Schilte C, Rohatgi A, et al.ISG15 is critical in the control of Chikungunya virus infection independent of UbE1L mediated conjugation[J]. PLoS Pathog, 2011, 7(10): e1002322. DOI:10.1371/journal.ppat.1002322 [38] Uhrlaub JL, Pulko V, Defilippis VR, et al.Dysregulated TGF-beta production underlies the age-related vulnerability to Chikungunya virus[J]. PLoS Pathog, 2016, 12(10): e1005891. DOI:10.1371/journal.ppat.1005891 [39] Hawman DW, Stoermer KA, Montgomery SA, et al.Chronic joint disease caused by persistent Chikungunya virus infection is controlled by the adaptive immune response[J]. J Virol, 2013, 87(24): 13878-13888. DOI:10.1128/jvi.02666-13 [40] Powers AM, Poo YS, Rudd PA, et al.Multiple immune factors are involved in controlling acute and chronic Chikungunya virus infection[J]. PLoS Negl Trop Dis, 2014, 8(12): e3354. DOI:10.1371/journal.pntd.0003354 [41] Riemersma KK S C, Singapuri A, Coffey LL. Chikungunya virus fidelity variants exhibit differential attenuation and population diversity in cell culture and adult mice[J]. J Virol, 2019, 93(3): 1-19. DOI:10.1128/JVI.01606-18 [42] Kuo SC, Wang YM, Ho YJ, et al.Suramin treatment reduces chikungunya pathogenesis in mice[J]. Antiviral Res, 2016, 134:89-96. DOI:10.1016/j.antiviral.2016.07.025 [43] Gao S, Song S, Zhang L.Recent progress in vaccine development against Chikungunya virus[J]. Front Microbiol, 2019, 10:2881. DOI:10.3389/fmicb.2019.02881 [44] Amdekar S, Parashar D, Alagarasu K.Chikungunya virus-induced arthritis: role of host and viral factors in the pathogenesis[J]. Viral Immunol, 2017, 30(10): 691-702. DOI:10.1089/vim.2017.0052 [45] Cook LE, Locke MC, Young AR, et al.Distinct roles of interferon alpha and beta in controlling Chikungunya virus replication and modulating neutrophil-mediated inflammation[J]. J Virol, 2019, 94(1): 1-16. DOI:10.1128/jvi.00841-19 [46] Gardner CL, Burke CW, Higgs ST, et al.Interferon-alpha/beta deficiency greatly exacerbates arthritogenic disease in mice infected with wild-type chikungunya virus but not with the cell culture-adapted live-attenuated 181/25 vaccine candidate[J]. Virology, 2012, 425(2): 103-112. DOI:10.1016/j.virol.2011.12.020 [47] Ngwe Tun MM, Muthugala R, Kyaw Kyaw A, et al.Pathogenetic potential relating to metabolic activity in a mouse model of infection with the Chikungunya virus East/Central/South African genotype[J]. Viruses, 2020, 12(169): 1-14. DOI:10.3390/v12020169 [48] Langsjoen RM, Haller SL, Roy CJ, et al.Chikungunya virus strains show lineage-specific variations in virulence and cross-protective ability in murine and nonhuman primate models[J]. mBio, 2018, 9(2): e02449-17. DOI:10.1128/mBio.02449-17 [49] Rudd PA, Wilson J, Gardner J, et al.Interferon response factors 3 and 7 protect against Chikungunya virus hemorrhagic fever and shock[J]. J Virol, 2012, 86(18): 9888-9898. DOI:10.1128/jvi.00956-12 [50] Delang L, Segura Guerrero N, Tas A, et al.Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral[J]. J Antimicrob Chemother, 2014, 69(10): 2770-2784. DOI:10.1093/jac/dku209 [51] Pal P, Dowd KA, Brien JD, et al.Development of a highly protective combination monoclonal antibody therapy against Chikungunya virus[J]. PLoS Pathog, 2013, 9(4): e1003312. DOI:10.1371/journal.ppat.1003312 [52] Her Z, Teng TS, Tan JJ, et al.Loss of TLR3 aggravates CHIKV replication and pathology due to an altered virus-specific neutralizing antibody response[J]. EMBO Mol Med, 2015, 7(1): 24-41. DOI:10.15252/emmm.201404459 [53] Lum FM, Teo TH, Lee WW, et al.An essential role of antibodies in the control of Chikungunya virus infection[J]. J Immunol, 2013, 190(12): 6295-6302. DOI:10.4049/jimmunol.1300304 [54] Diemert DJ, Seymour RL, Adams AP, et al.A rodent model of Chikungunya virus infection in RAG1-/- mice, with features of persistence, for vaccine safety evaluation[J]. PLoS Negl Trop Dis, 2015, 9(6): e0003800. DOI:10.1371/journal.pntd.0003800 [55] Carissimo G, Teo TH, Chan YH, et al.Viperin controls chikungunya virus-specific pathogenic T cell IFN gamma Th1 stimulation in mice[J]. Life Sci Alliance, 2019, 2(1): 1-13. DOI:10.26508/lsa.201900298 [56] Long KM, Ferris MT, Whitmore AC, et al.γδ T cells play a protective role in Chikungunya virus-induced disease[J]. J Virol, 2016, 90(1): 433-443. DOI:10.1128/JVI.02159-15 [57] Hucke FI, Bugert JJ.Current and promising antivirals against Chikungunya virus[J]. Front Public Health, 2020, 8:618-624. DOI:10.3389/fpubh.2020.618624 [58] Matusali G, Colavita F, Bordi L, et al.Tropism of the Chikungunya virus[J]. Viruses, 2019, 11(2): 175. DOI:10.3390/v11020175